Developer docs
API playgroundTry for free, no card

Search company profiles

VSY Biotechnology

Full company profile

uuid00076hr

Namestring
VSY Biotechnology
Legal namestring
VSY Biotechnology GmbH
Company typeenum
Private
Founded yearint
2009
Descriptiontext

VSY Biotechnology GmbH is a German-headquartered, privately held medical device manufacturer founded in 2009 and based in Leinfelden-Echterdingen near Stuttgart, employing 251–500 staff. The company develops, manufactures and sells ophthalmology-focused products including intraocular lenses (IOLs) and supporting surgical devices, with additional revenue streams in orthobiologic viscosupplementation and hyaluronic-acid-based medical aesthetics.

Its core product architecture is built around two IOL platforms: the Enova Family of preloaded, 100% Glistening-Free hydrophobic IOLs (including Enova Maestro with Sinusoidal Vision Technology (SVT®), Enova Advanced® EDoF, and Enova Monofocal variants) and the AcrivaUD Family of pupil-adaptive hydrophobic surface IOLs (including Acriva Trinova, Trinova Pro, and toric versions). Supporting surgical products include the patented Rotaryjet™ Preloaded Delivery System, the Acrijetfly cartridge injector, and the Protectalon line of bio-fermented sodium hyaluronate viscoelastics offered in seven concentrations. Orthobiologic and aesthetic lines (Recross, Reviscon, Joy, Shine, Shape, Berry, Eyes) extend the hyaluronic acid manufacturing capability into adjacent verticals.

VSY operates a B2B enterprise model selling to ophthalmologists, eye surgeons, and clinics, primarily through a network of regional distributors accessed via the VSYOphthalmologyDistributorHub and direct enterprise sales. Pricing is quote-based with standard 30-day invoice terms. The company maintains MDSAP quality certification, holds patents in China (SVT®) and at the European Patent Institute (Rotaryjet™), and has entered Japan via a 2021 licensing partnership with Wakamoto Pharmaceutical. Annual ESCRS congress participation and the Ophthalmology Star Awards programme anchor its go-to-market with European and international ophthalmic surgeons.

Short descriptiontext

VSY Biotechnology GmbH is a Germany-based medical device manufacturer developing premium intraocular lenses, viscoelastics, orthobiologics, and medical aesthetics for ophthalmologists, surgeons, and clinics globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLeinfelden-echterdingen, Germany
HQ citystring
Leinfelden-echterdingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic medical devices, intraocular lenses, cataract surgery products, viscoelastic solutions, orthobiologic injections
Industry1 code
PRIMARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Intraocular Lens (IOL) Sales
TypeHardware Sales
Description

Sale of premium intraocular lenses including the Enova and Acriva families. Products include monofocal, trifocal, extended depth of focus (EDoF), and toric models for cataract and refractive surgery.

vsybiotechnology.com
2Viscoelastic Products
TypeHardware Sales
Description

Protectalon brand bio-fermented sodium hyaluronate products for smooth ophthalmic surgeries. Available in 7 different concentrations.

vsybiotechnology.com
3Cartridge Injector Systems
TypeHardware Sales
Description

Sale of Rotaryjet preloaded delivery systems and Acrijet cartridge injector systems for IOL delivery.

vsybiotechnology.com
4Orthobiologics
TypeHardware Sales
Description

Recross and Reviscon hyaluronic acid products for orthopedic applications providing long-lasting pain relief through IA-HA solutions.

vsybiotechnology.com
5Medical Aesthetics
TypeHardware Sales
Description

Hyaluronic acid-based aesthetic products (Joy, Shine, Shape, Berry, Eyes) for medical aesthetics applications.

vsybiotechnology.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Enova Family
Description

Preloaded 100% Glistening-Free Hydrophobic IOL Platform featuring products like Enova Maestro (presbyopia), Enova Advanced EDoF IOL, and Enova Monofocal

vsybiotechnology.com
+5 more records
Core offering1 text field

VSY Biotechnology GmbH develops, designs, and manufactures medical devices and biotechnology products primarily for ophthalmology, with additional offerings in orthobiologics and medical aesthetics. The company sells intraocular lenses (IOLs), viscoelastic solutions, preloaded and cartridge injector delivery systems, and hyaluronic acid-based orthobiologic and aesthetic products to healthcare professionals, clinics, and distributor partners worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 10%+ market share in German cataract surgeries with Protectalon
+1 more record
Product overview1 text field

VSY Biotechnology GmbH offers a diversified portfolio of medical devices and biotechnology products spanning ophthalmology, aesthetics, and orthobiologics. The core ophthalmology business centers on the Enova Family of preloaded 100% glistening-free hydrophobic IOLs (including Enova Maestro, Enova Advanced, and Enova Monofocal variants) and the AcrivaUD Family of hydrophobic surface IOLs. The company also provides supporting surgical products including the Rotaryjet Preloaded Delivery System, Acrijetfly cartridge injector, and Protectalon viscoelastics. In orthobiologics, VSY Biotechnology offers Recross and Reviscon hyaluronic acid-based solutions for pain management. The product architecture is organized as distinct platform families with specialized variants (toric, presbyopia-correcting) and complementary delivery/injection systems.

Product and service14 records
1Enova Maestro
CategoryIntraocular Lens (IOL)
Description

Presbyopia-correcting intraocular lens featuring Sinusoidal Vision Technology (SVT) for enhanced visual outcomes after cataract surgery, targeting ophthalmologists and cataract surgeons.

2Enova Advanced
CategoryIntraocular Lens (IOL)
Description

Extended Depth of Focus (EDoF) intraocular lens with Light Tailoring Technology for next-generation vision correction after cataract surgery.

3Enova Monofocal
CategoryIntraocular Lens (IOL)
Description

Standard monofocal intraocular lens for cataract surgery, available in standalone and toric variants, made from 100% Glistening-Free hydrophobic material.

4Enova Maestro Toric
CategoryIntraocular Lens (IOL)
Description

Toric version of the Enova Maestro IOL with Sinusoidal Vision Technology for correction of astigmatism during cataract surgery.

5Enova Advanced Toric
CategoryIntraocular Lens (IOL)
Description

Toric version of the Enova Advanced EDoF IOL for cataract patients with astigmatism.

6Rotaryjet Preloaded Delivery System
CategoryIOL Delivery System
Description

Patented preloaded injector system for delivery of hydrophobic intraocular lenses, featuring visual and audible feedback and a push-and-pull mechanism for safe insertion.

7Acriva Trinova
CategoryIntraocular Lens (IOL)
Description

Hydrophobic surface intraocular lens platform with pupil-adaptive technology for cataract surgery.

8Acriva Trinova Pro
CategoryIntraocular Lens (IOL)
Description

Enhanced version of Acriva Trinova with advanced pupil-adaptive technology, positioned as a presbyopia-correcting IOL with patented enhanced technology.

9Acriva
CategoryIntraocular Lens (IOL)
Description

Hydrophobic surface intraocular lens platform for cataract surgery.

10Acriva Toric
CategoryIntraocular Lens (IOL)
Description

Toric version of Acriva IOL for astigmatism correction during cataract surgery.

11Acrijetfly Cartridge Injector System
CategoryIOL Delivery System
Description

Cartridge injector system with semi-translucent design, locking system, and Railguard design for optimized intraocular lens loading.

12Protectalon
CategoryOphthalmic Viscoelastic
Description

Viscoelastic product line made from bio-fermented sodium hyaluronate in 7 different concentrations, used for smooth and confident ophthalmic surgeries.

13Recross
CategoryOrthobiologic Injection
Description

One-shot intra-articular hyaluronic acid (IA-HA) solution for long-lasting joint pain relief in orthopedic applications.

14Reviscon
CategoryOrthobiologic Injection
Description

Linear sodium hyaluronate product in three concentrations (20mg 1.0%, 32mg 1.6%, 48mg 2.0%) for orthopedic viscosupplementation applications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-19
Description

VSY Biotechnology signed an agreement with WAKAMOTO PHARMACEUTICAL for licensing arrangement to develop and launch intraocular lens products in Japan. This partnership represents VSY's entry into the Japanese medical device market, with WAKAMOTO leveraging their existing ophthalmology presence in Japan.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership with Clarius Mobile Health Corp. mentioned as a collaboration in the biotechnology and medical device sector, though specific details of the partnership scope are limited in available materials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest ophthalmic medical device company and the global IOL market leader (PanOptix, Vivity families). Directly competes with VSY across monofocal, toric, EDoF, and presbyopia-correcting IOLs and has the broadest distribution and clinical-evidence infrastructure.

TypeBroad incumbent
Description

Through Hoya Surgical Optics, markets the Vivinex and iSert preloaded IOL systems globally, directly competing with VSY's Enova preloaded platform and Rotaryjet injector technology.

TypeDirect peer
Description

German-headquartered ophthalmic implant manufacturer offering IOLs and corneal implants. Directly comparable mid-sized European competitor in the cataract surgery device space and a fellow DACH-market rival.

TypeBroad incumbent
Description

Markets the enVista and LuxSmart IOL platforms and competes in the premium IOL segment with VSY, particularly in Europe. Also sells ophthalmic viscoelastic devices, overlapping directly with VSY's Protectalon line.

TypeDirect peer
Description

Belgian premium IOL specialist (FineVision, Pod, Isopure families) competing directly in trifocal and EDoF IOLs — overlapping with VSY's Acriva Trinova and Enova Advanced product lines.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

German-headquartered ophthalmic systems leader offering the CT LUCIA and CT SPHERIS IOL families alongside surgical microscopes and diagnostics. A directly comparable peer for VSY's premium IOL portfolio and a fellow DACH-based competitor.

TypeBroad incumbent
Description

Operates the TECNIS IOL platform (monofocal, multifocal, EDoF, toric, Symfony) and competes head-to-head with VSY's AcrivaUD and Enova families. Backed by J&J's global cataract surgery salesforce and surgeon education programs.

8Santen Pharmaceutical
TypeDirect peer
Description

Japan-headquartered ophthalmology specialist with a portfolio of intraocular lenses and surgical devices. Directly comparable peer for VSY's premium IOL franchise and an obvious potential partner or competitor in the Japanese market where VSY has partnered with Wakamoto.

TypeDirect peer
Description

Spun out of Oculentis and focused on premium IOLs (Lentis family) including multifocal and EDoF designs. Closely comparable in scale, premium-IOL focus, and European footprint — directly competes with VSY's AcrivaUD and Enova platforms.

10Lenstec
TypeDirect peer
Description

Privately held medical device company focused on intraocular lenses including the Tetraflex and SBL-3 platforms. Comparable mid-sized peer competing in premium cataract IOLs with a similar specialty-only positioning to VSY.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VSY Biotechnology

Ophthalmic Medical Devicesvsybiotechnology.com

VSY Biotechnology GmbH is a Germany-based medical device manufacturer developing premium intraocular lenses, viscoelastics, orthobiologics, and medical aesthetics for ophthalmologists, surgeons, and clinics globally.

What VSY Biotechnology does

VSY Biotechnology GmbH is a German-headquartered, privately held medical device manufacturer founded in 2009 and based in Leinfelden-Echterdingen near Stuttgart, employing 251–500 staff. The company develops, manufactures and sells ophthalmology-focused products including intraocular lenses (IOLs) and supporting surgical devices, with additional revenue streams in orthobiologic viscosupplementation and hyaluronic-acid-based medical aesthetics.

Its core product architecture is built around two IOL platforms: the Enova Family of preloaded, 100% Glistening-Free hydrophobic IOLs (including Enova Maestro with Sinusoidal Vision Technology (SVT®), Enova Advanced® EDoF, and Enova Monofocal variants) and the AcrivaUD Family of pupil-adaptive hydrophobic surface IOLs (including Acriva Trinova, Trinova Pro, and toric versions). Supporting surgical products include the patented Rotaryjet™ Preloaded Delivery System, the Acrijetfly cartridge injector, and the Protectalon line of bio-fermented sodium hyaluronate viscoelastics offered in seven concentrations. Orthobiologic and aesthetic lines (Recross, Reviscon, Joy, Shine, Shape, Berry, Eyes) extend the hyaluronic acid manufacturing capability into adjacent verticals.

VSY operates a B2B enterprise model selling to ophthalmologists, eye surgeons, and clinics, primarily through a network of regional distributors accessed via the VSYOphthalmologyDistributorHub and direct enterprise sales. Pricing is quote-based with standard 30-day invoice terms. The company maintains MDSAP quality certification, holds patents in China (SVT®) and at the European Patent Institute (Rotaryjet™), and has entered Japan via a 2021 licensing partnership with Wakamoto Pharmaceutical. Annual ESCRS congress participation and the Ophthalmology Star Awards programme anchor its go-to-market with European and international ophthalmic surgeons.

VSY Biotechnology firmographics

Firmographics
Name
VSY Biotechnology
Legal name
VSY Biotechnology GmbH
Website
https://vsybiotechnology.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
VSY Biotechnology GmbH is a Germany-based medical device manufacturer developing premium intraocular lenses, viscoelastics, orthobiologics, and medical aesthetics for ophthalmologists, surgeons, and clinics globally.
Ownership category
akta.pro rank

VSY Biotechnology industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic medical devices
  • Intraocular lenses
  • Cataract surgery products
  • Viscoelastic solutions
  • Orthobiologic injections

Where VSY Biotechnology is headquartered

Location

Headquarters

HQ city
Leinfelden-echterdingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

VSY Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Intraocular Lens (IOL) Sales: Sale of premium intraocular lenses including the Enova and Acriva families. Products include monofocal, trifocal, extended depth of focus (EDoF), and toric models for cataract and refractive surgery.
  2. Viscoelastic Products: Protectalon brand bio-fermented sodium hyaluronate products for smooth ophthalmic surgeries. Available in 7 different concentrations.
  3. Cartridge Injector Systems: Sale of Rotaryjet preloaded delivery systems and Acrijet cartridge injector systems for IOL delivery.
  4. Orthobiologics: Recross and Reviscon hyaluronic acid products for orthopedic applications providing long-lasting pain relief through IA-HA solutions.
  5. Medical Aesthetics: Hyaluronic acid-based aesthetic products (Joy, Shine, Shape, Berry, Eyes) for medical aesthetics applications.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

VSY Biotechnology product offering

Product offering

Core offering

VSY Biotechnology GmbH develops, designs, and manufactures medical devices and biotechnology products primarily for ophthalmology, with additional offerings in orthobiologics and medical aesthetics. The company sells intraocular lenses (IOLs), viscoelastic solutions, preloaded and cartridge injector delivery systems, and hyaluronic acid-based orthobiologic and aesthetic products to healthcare professionals, clinics, and distributor partners worldwide.

Product overview

VSY Biotechnology GmbH offers a diversified portfolio of medical devices and biotechnology products spanning ophthalmology, aesthetics, and orthobiologics. The core ophthalmology business centers on the Enova Family of preloaded 100% glistening-free hydrophobic IOLs (including Enova Maestro, Enova Advanced, and Enova Monofocal variants) and the AcrivaUD Family of hydrophobic surface IOLs. The company also provides supporting surgical products including the Rotaryjet Preloaded Delivery System, Acrijetfly cartridge injector, and Protectalon viscoelastics. In orthobiologics, VSY Biotechnology offers Recross and Reviscon hyaluronic acid-based solutions for pain management. The product architecture is organized as distinct platform families with specialized variants (toric, presbyopia-correcting) and complementary delivery/injection systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Enova Family: Preloaded 100% Glistening-Free Hydrophobic IOL Platform featuring products like Enova Maestro (presbyopia), Enova Advanced EDoF IOL, and Enova Monofocal
  • AcrivaUD Family
  • Protectalon
  • Rotaryjet
  • Sinusoidal Vision Technology (SVT®)
  • Golden Ratio in IOL Technology™

Products and services

  • Enova Maestro Presbyopia-correcting intraocular lens featuring Sinusoidal Vision Technology (SVT) for enhanced visual outcomes after cataract surgery, targeting ophthalmologists and cataract surgeons.
  • Enova Advanced Extended Depth of Focus (EDoF) intraocular lens with Light Tailoring Technology for next-generation vision correction after cataract surgery.
  • Enova Monofocal Standard monofocal intraocular lens for cataract surgery, available in standalone and toric variants, made from 100% Glistening-Free hydrophobic material.
  • Enova Maestro Toric Toric version of the Enova Maestro IOL with Sinusoidal Vision Technology for correction of astigmatism during cataract surgery.
  • Enova Advanced Toric Toric version of the Enova Advanced EDoF IOL for cataract patients with astigmatism.
  • Rotaryjet Preloaded Delivery System Patented preloaded injector system for delivery of hydrophobic intraocular lenses, featuring visual and audible feedback and a push-and-pull mechanism for safe insertion.
  • Acriva Trinova Hydrophobic surface intraocular lens platform with pupil-adaptive technology for cataract surgery.
  • Acriva Trinova Pro Enhanced version of Acriva Trinova with advanced pupil-adaptive technology, positioned as a presbyopia-correcting IOL with patented enhanced technology.
  • Acriva Hydrophobic surface intraocular lens platform for cataract surgery.
  • Acriva Toric Toric version of Acriva IOL for astigmatism correction during cataract surgery.
  • Acrijetfly Cartridge Injector System Cartridge injector system with semi-translucent design, locking system, and Railguard design for optimized intraocular lens loading.
  • Protectalon Viscoelastic product line made from bio-fermented sodium hyaluronate in 7 different concentrations, used for smooth and confident ophthalmic surgeries.
  • Recross One-shot intra-articular hyaluronic acid (IA-HA) solution for long-lasting joint pain relief in orthopedic applications.
  • Reviscon Linear sodium hyaluronate product in three concentrations (20mg 1.0%, 32mg 1.6%, 48mg 2.0%) for orthopedic viscosupplementation applications.

Quantifiable outcome

  • 10%+ market share in German cataract surgeries with Protectalon
  • +1 more outcomes

Companies that use VSY Biotechnology

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

VSY Biotechnology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

VSY Biotechnology partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • WAKAMOTO PHARMACEUTICAL CO., LTD.coreChannel Partner/ Reseller/ Distributor · 19 March 2021VSY Biotechnology signed an agreement with WAKAMOTO PHARMACEUTICAL for licensing arrangement to develop and launch intraocular lens products in Japan. This partnership represents VSY's entry into the Japanese medical device market, with WAKAMOTO leveraging their existing ophthalmology presence in Japan.
  • Clarius Mobile Health Corp.minorStrategic or Co-development PartnerStrategic partnership with Clarius Mobile Health Corp. mentioned as a collaboration in the biotechnology and medical device sector, though specific details of the partnership scope are limited in available materials.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

VSY Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Alcon: World's largest ophthalmic medical device company and the global IOL market leader (PanOptix, Vivity families). Directly competes with VSY across monofocal, toric, EDoF, and presbyopia-correcting IOLs and has the broadest distribution and clinical-evidence infrastructure.
  • Hoya Corporation (Vision Care): Through Hoya Surgical Optics, markets the Vivinex and iSert preloaded IOL systems globally, directly competing with VSY's Enova preloaded platform and Rotaryjet injector technology.
  • Bausch + Lomb: Markets the enVista and LuxSmart IOL platforms and competes in the premium IOL segment with VSY, particularly in Europe. Also sells ophthalmic viscoelastic devices, overlapping directly with VSY's Protectalon line.
  • Carl Zeiss Meditec: German-headquartered ophthalmic systems leader offering the CT LUCIA and CT SPHERIS IOL families alongside surgical microscopes and diagnostics. A directly comparable peer for VSY's premium IOL portfolio and a fellow DACH-based competitor.
  • Johnson & Johnson Vision: Operates the TECNIS IOL platform (monofocal, multifocal, EDoF, toric, Symfony) and competes head-to-head with VSY's AcrivaUD and Enova families. Backed by J&J's global cataract surgery salesforce and surgeon education programs.

Direct peers

  • HumanOptics: German-headquartered ophthalmic implant manufacturer offering IOLs and corneal implants. Directly comparable mid-sized European competitor in the cataract surgery device space and a fellow DACH-market rival.
  • PhysIOL: Belgian premium IOL specialist (FineVision, Pod, Isopure families) competing directly in trifocal and EDoF IOLs — overlapping with VSY's Acriva Trinova and Enova Advanced product lines.
  • Santen Pharmaceutical: Japan-headquartered ophthalmology specialist with a portfolio of intraocular lenses and surgical devices. Directly comparable peer for VSY's premium IOL franchise and an obvious potential partner or competitor in the Japanese market where VSY has partnered with Wakamoto.
  • Teleon Surgical: Spun out of Oculentis and focused on premium IOLs (Lentis family) including multifocal and EDoF designs. Closely comparable in scale, premium-IOL focus, and European footprint — directly competes with VSY's AcrivaUD and Enova platforms.
  • Lenstec: Privately held medical device company focused on intraocular lenses including the Tetraflex and SBL-3 platforms. Comparable mid-sized peer competing in premium cataract IOLs with a similar specialty-only positioning to VSY.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VSY Biotechnology social profiles

Digital presence

VSY Biotechnology compliance and trust

Trust signal

Compliance1 record

VSY Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VSY Biotechnology leadership team

Management profile

Number of profiles

Profiles1 record

VSY Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VSY Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VSY Biotechnology

What does VSY Biotechnology do?

VSY Biotechnology GmbH develops, designs, and manufactures medical devices and biotechnology products primarily for ophthalmology, with additional offerings in orthobiologics and medical aesthetics. The company sells intraocular lenses (IOLs), viscoelastic solutions, preloaded and cartridge injector delivery systems, and hyaluronic acid-based orthobiologic and aesthetic products to healthcare professionals, clinics, and distributor partners worldwide.

Is VSY Biotechnology a public or private company?

VSY Biotechnology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was VSY Biotechnology founded?

VSY Biotechnology was founded in 2009. It employs 101 to 250 people.

Where is VSY Biotechnology based?

VSY Biotechnology is headquartered in Leinfelden-echterdingen, Germany, in the Europe region.

How does VSY Biotechnology make money?

Five revenue lines are on record. Intraocular Lens (IOL) Sales are the primary driver. The others are viscoelastic Products, cartridge Injector Systems, orthobiologics and medical Aesthetics.

Who are VSY Biotechnology's main competitors?

Broad incumbents on record are Alcon, Hoya Corporation (Vision Care), Bausch + Lomb, Carl Zeiss Meditec and Johnson & Johnson Vision. Direct peers are HumanOptics, PhysIOL, Santen Pharmaceutical, Teleon Surgical and Lenstec.

Does VSY Biotechnology have an API?

No public API is recorded for VSY Biotechnology.

What industry is VSY Biotechnology in?

VSY Biotechnology's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEVMANN takes under its umbrella two innovative, fast-growing companiesEvmann Investments Holding BV has consolidated the operations of VSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH under its umbrella as part of a global growth strategy. The two German-based companies, which operate in ophthalmology and orthopedics across more than 90 countries, will now function within a single global framework managed by Evmann from Amsterdam. This restructuring aims to accelerate R&D investments and expand into new therapeutic fields with the goal of achieving unicorn status.PR NewswireEVMANN prend sous son aile deux entreprises innovantes et en forte croissanceVSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH, two German medtech companies operating in ophthalmology and orthopedics across more than 90 countries, consolidated their operations under Evmann Investments Holding BV in the Netherlands as part of a global growth strategy initiated in early 2021. The combined entity, with approximately 300 employees and 14,000 square meters of manufacturing and distribution facilities in Germany and Turkey, aims to accelerate growth through expanded R&D investments and new therapeutic areas, targeting unicorn status with a valuation of €1 billion.PR NewswireEVMANN übernimmt zwei innovative, wachstumsstarke UnternehmenVSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH, both Germany-based companies specializing in ophthalmology and orthopedics, announced they will consolidate their operations under Evmann Investments Holding BV in the Netherlands as part of their international growth strategy initiated in early 2021. The combined entity will bring together over 300 employees and 14,000 square meters of production and distribution facilities in Germany and Turkey, serving more than 90 countries across six continents. Evmann stated it aims to become a unicorn valued at €1 billion and plans to expand into additional therapeutic areas beyond ophthalmology and orthopedics.PR NewswireEVMANN acoge bajo su paraguas a dos empresas innovadoras y de rápido crecimientoEvmann Investments Holding BV has consolidated the operations of VSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH under its umbrella as part of a global growth strategy initiated in early 2021. The two German subsidiaries, which manufacture ophthalmology and orthopedic products sold in over 90 countries, will now operate within Evmann's structure to accelerate R&D investments and expansion into new therapeutic fields.PR NewswireA New Drug to Treat COVID-19, TR-C 19 is Now Ready for Human TestingVSY Biotechnology GmbH announced the development of a new COVID-19 treatment drug called TR-C 19, which laboratory studies have shown can neutralize the virus under controlled conditions. The company has submitted the drug for regulatory approval to begin clinical trials on voluntary COVID-19 patients, with health authorities accelerating their evaluation due to the public health emergency. Clinical and voluntary trials will be organized in partnership with SBU, with initial patient trial results expected to be shared publicly in the coming weeks.PR NewswireVSY Biotechnology BV and Carl Zeiss Meditec AG Settled Their Legal DisputesVSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced the resolution of their legal and patent disputes concerning Tri-ED 611, with both parties agreeing to keep the settlement terms confidential. The settlement ends a known legal conflict between the two companies in the biotechnology and medical technology sectors. No further details about the resolution or its financial implications were disclosed.PR NewswireThe German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss MeditecA German court has granted a preliminary injunction in favor of VSY Biotechnology BV and against Carl Zeiss Meditec AG, ruling in VSY's favor in an action alleging that Zeiss provided misleading information to the public in one of its press releases. VSY Biotechnology, headquartered in Amsterdam, had filed opposition against a Zeiss patent as part of the legal action. The CEO of VSY Biotechnology called the ruling a victory and outlined the company's growth strategy, including operations in 55 countries and plans to release 32 new ophthalmic products within four years.PR NewswireLes tribunaux allemands ont accordé une injonction préliminaire en faveur de VSY Biotechnology BV, à l'encontre de Carl Zeiss MeditecGerman courts granted a preliminary injunction in favor of VSY Biotechnology BV against Carl Zeiss Meditec AG in a legal action founded on allegations that Zeiss provided misleading information to the public in a press release. VSY Biotechnology, an Amsterdam-based ophthalmology company ranked 13th among 75 global intraocular lens manufacturers, declared the ruling a victory and reaffirmed its growth ambitions, including plans to launch 32 new ophthalmic products over the next four years. The court decision document is available in the referenced case file.PR NewswireAffaire de brevet entre Carl Zeiss Meditec AG et VSY Biotechnology B.V.Carl Zeiss Meditec AG reported a victory in a patent infringement lawsuit at the District Court of Düsseldorf against VSY Biotechnology B.V. and its supplier Fritz Ruck Ophthalmologische GmbH regarding European patent EP 2 377 493 B1. VSY Biotechnology announced it intends to appeal the decision to higher German courts and has simultaneously filed an opposition with the European Patent Office to invalidate the patent, citing a lack of inventiveness.